Don’t miss the latest developments in business and finance.

Akorn-Strides JV submits first ANDA

Image
Our Bureau Bangalore
Last Updated : Jan 28 2013 | 6:03 PM IST
 According to an official release issued today, the proposed drug is a parenteral injectable supporting the antiemetic market, which has annual sales of nearly $600 million. Patent protection for the reference-listed drug expires in September 2008.

 Arun Kumar, executive vice chairman and MD of Strides Arcolab, said: "The first ANDA filing is an important milestone for the Akorn-Strides joint venture, which further strengthens the partnership between Akorn and Strides."

  

More From This Section

First Published: Apr 04 2006 | 4:14 PM IST

Next Story